IBA highlights how its Proteus solutions and network of partners are shaping the future of proton therapy at ESTRO

California Auction Event Closing TOMORROW - Bid Now

IBA highlights how its Proteus solutions and network of partners are shaping the future of proton therapy at ESTRO

Press releases may be edited for formatting or style | November 30, 2020 Rad Oncology Proton Therapy
Louvain-la-Neuve, Belgium, November 27, 2020 – IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions, will highlight how its Proteus solutions, as well as its collaboration with its partners are shaping the future of proton therapy during the Annual Congress and Exhibition of the European Society for Radiotherapy & Oncology (ESTRO) being held online from November 28th to December 1st, 2020.

With an unrivaled, full dedication to proton therapy as a treatment modality, IBA has developed the largest and most knowledgeable community of proton therapy users over the last 20 years. To date, IBA's 36 clinical partners in operation have treated over 100,000 patients with proton therapy.

Together with its customers as well as industry partners such as Elekta, RaySearch and Philips, IBA is shaping the future of proton therapy by developing the proton therapy systems and dosimetry solutions that will allow the treatment of more patients with increased accuracy.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.



First, IBA's comprehensive Motion Management package will help clinicians to treat more indications more confidently as demonstrated by UMC Groningen where lung and breast indications currently represent 35% of indications treated in 2020.

Additionally, IBA's unique Proton Arc Therapy1 is developed to enable clinicians to deliver faster, simpler and sharper treatment. "Our initial work on plan comparisons between Proton Arc Therapy and IMPT shows a reduction in the mean dose (Dmean) ranging from 4% to 20% on selected organs at risk, resulting in a 3-4% reduction in Normal Tissue Complication Probability (NTCP)", commented Professor Hans Langendijk from UMC Groningen. "This will most likely increase the number of patients eligible for proton therapy, when applying the model based approach approved in The Netherlands."

Finally, IBA and its clinical partners are committed to bring Flash Therapy1 into the clinic, given its tremendous potential to radically change the radiation therapy landscape and revolutionize cancer care in general. In addition to IBA's yearly investment of over EUR 20 million in particle accelerators, the company received funding in October 2020, from the Walloon region² in Belgium for a research project on FLASH therapy worth EUR 4.4 Million.

IBA is also involved in a scientific consortium as a scientific adviser, a number of EU projects as an external collaborator (not funded), such as UHDpulse (http://uhdpulse-empir.eu/) and as a partner in the INSPIRE project (https://protonsinspire.eu/).

You Must Be Logged In To Post A Comment